Refine by
Pharmaceuticals To Present Clinical Articles & Analysis
73 news found
Boston: “According to the latest BCC Research study, the demand for Medical Kiosks: Global Market and Forecasts is estimated to increase from $1.4 billion in 2022 to reach $3.2 billion by 2028, at a compound annual growth rate (CAGR) of 14.8% from 2022 through 2028.” The comprehensive report on the medical kiosks market delivers a thorough analysis of its current landscape and future ...
The company also provides Forecasting Modeling services to predict future sales and product demand by statistical models, as well as Data Visualization and Reporting services that present the results of the analysis through visualization and reporting. ...
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional and accredited investors for $5.8 million of common stock. The Company issued a total of 2,900,000 shares of common stock at a purchase price of ...
(Nasdaq:LIXT) today announced it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 investor conference Wednesday, December 7, 2022 at 3:30 p.m. ...
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data from our Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD). The KOL webinar will ...
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34th Annual Healthcare Conference November 29th through December 1st. Event: Piper Sandler 34th Annual ...
DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced the speaker lineup for its customer presentations at the American Society of Human Genetics (ASHG) 2022 Annual Meeting, which is being held in Los Angeles this week. ...
Iterative Health, formerly known as Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, has announced a rebrand to reflect the company’s success in utilizing artificial intelligence (AI) to strengthen clinical research and augment clinical decision making within gastroenterology. In this new chapter, Iterative Health will continue to focus on its core ...
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for enhancements to its LungPrint solution, including automated deep learning-based lung and lobe segmentation algorithms. This clearance further validates the quality and clinical efficacy of the ...
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced that the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) has authorized a Phase 1b/randomized Phase 2 study of ...
Pravibismane has also demonstrated safety in multiple clinical studies including treatment of patients with diabetic foot infections and patients with serious orthopedic device-related infections. Several positive signals of efficacy (not statistically significant) were appreciated in these early clinical studies. About Microbion Microbion is a ...
STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced the worldwide in-licensing of SFX-01 from Evgen Pharma plc (Evgen) in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-characterized subgroup of patients with Autism ...
BySTALICLA
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane. The patent, titled “Bismuth-thiol compositions and methods for treating wounds,” adds to Microbion’s growing portfolio of intellectual property on the ...
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October. Event: Cantor Neurology ...
Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, today announces that Destiny Pharma’s CEO, Neil Clark, will present virtually at the upcoming HC Wainwright 24th Annual Global Investment Conference, being held on 12-14 September 2022 in New York and virtually. The presentation will be ...
XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to congratulate Prof. Dr. Raimar Loebenberg as the 2022 recipient of the CSPS Award of Leadership in Canadian Pharmaceutical Sciences. Dr. Loebenberg is a Professor in the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta (“UoA”), the founder ...
EsoCap has announced that scientists from the University of Greifswald have published important data regarding a hot-melt extrusion-based spinning process to produce pharmaceutical fibers and yarns. This spinning process is very useful in the context of EsoCap’s novel drug delivery technology, enabling targeted and long-lasting local therapy of the esophagus. The rapidly dissolving yarn is ...
ARLINGTON, Mass., May 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported clinical data from a Phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the ...
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announces that Professor René Bernards, Netherlands Cancer Institute (NKI), Amsterdam, presented new data from promising drug combinations of LIXTE’s lead clinical ...
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and other specific life-threatening conditions, announced today the addition of K. Chris Min, M.D., Ph.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (CMO), effective April 4, 2022. Dr. Min will lead global ...